1 SUPPLEMENTAL TEXT

2 1 Causal eQTL Fine-mapping Functional Annotations

3 *1.1* Brain: *MTCH2*

4 We retained the strength of our initially identified AD-TWAS association with *MTCH2*

5 genetically-regulated expression using the causal eQTLs identified by SuSiE [1] fine-

6 mapping and later applied to the OTTERS pipeline. While all OTTERS methods

7 produced models that were significantly associated with AD, the most parsimonious

8 model was generated by the lassosum method which retained only a single causal

9 eQTL (p_{Lassosum} = 3.53×10⁻⁸; z_{Lassosum} = -5.51). This causal eQTL

10 (chr11_47594246_G_C_b38; Effect Size = 0.30) was positively associated with *MTCH2*

11 expression and falls with several epigenomic marks associated with active enhancers

and promoters including H3K4me1, H3K4me3, H3K9ac, H3K27ac, and regions of open-

13 chromatin (DNase-seq, ATAC-seq, ChIA-PET CTCF peaks) based on FILER

14 annotations.

Previously, Gockley et al. 2021 found MTCH2 genetically-regulated gene expression 15 was negatively associated with AD risk (Model: bslmm; z_{TWAS} = -5.73; p_{TWAS} = 1.02×10⁻ 16 17 ⁸) [2]. In this study, researchers used six neo-cortical brain tissues (N RNA-seq = 888) and five different genetically-regulated expression modeling approaches (blup, bslmm, 18 19 lasso, top1, and enet) for Stage I of the AD-TWAS. Notably, the training sample used in 20 this prior study is approximately 34% of the size of the MetaBrain Brain Cortex dataset (N = 2,683) [2,3]. We further investigated whether any of the identified causal eQTLs 21 22 either identified by SuSiE and/or later selected by the OTTERS modeling methods using 23 the fine-mapped causal eQTLs overlapped with the reported variants included in the

models produced by Gockley et al. 2021 [2]. We lifted down the credible causal eQTLs
identified initially using SuSiE fine-mapping and the set of variants selected by the
OTTERS modeling approaches using the UCSC browser (https://genome.ucsc.edu/cgibin/hgLiftOver) with the original assembly as GRCh38/hg38 and the new assembly
GRCh37/hg19. We downloaded the available models (GRCh37) from this prior work
using the following link

30 (https://adknowledgeportal.synapse.org/Explore/Studies/DetailsPage?Study=syn223137

85). For *MTCH2*, none of the identified causal eQTLs initially identified by SuSiE and/or
later used by the OTTERS approach were found within any of the five models produced
by Gockley et al. 2021. These results illustrate the importance of fine-mapping causal
eQTL variants to understand the key variants driving TWAS associations.

35 *1.2* Brain: CYB561

36 The CYB561 OTTERS association was driven originally by the SDPR approach

37 modeling 1,616 SNPs (ACAT-O_{CON} $p = 1.99 \times 10^{-33}$; $p_{SDPR_CON} = 3.98 \times 10^{-34}$; $z_{SDPR} = -9.83$;

 R^{2} spr = 28.1%). Fine-mapping identified seven credible sets each containing a single

causal eQTL SNP. OTTERS analysis of these SNPs identified a six SNP SDPR model

40 with nearly identical performance (R^{2} _{SDPR} = 24%) and produced a TWAS result of similar

significance ($p_{SDPR} = 1.8 \times 10^{-20}$; $z_{SDPR} = -9.3$) We further explored the functional

42 annotations associated with the six SNPs within the SDPR model. There were two

43 SNPs (chr17_62990456_A_T_b38 & chr17_63325078_G_A_b38) that were positively

44 associated with CYB561 expression and these SNPs shared H3K4me1 marks

indicating active or poised enhancers. In comparison, the remaining four SNPs were

⁴⁶ negatively associated with the expression of *CYB561* and while they all shared

H3K36me3 histone marks, which are general indicators of active transcription and
prevention of spurious transcription initiation, they also all shared markers of
heterochromatin with histone marks of either H3K9me3 (chr17_63111035_G_A_b38,
chr17_63183402_G_A_b38, and chr17_63222967_C_T_b38) or H3K27me3
(chr17_63323907_G_A_b38). Overall, these results highlight the biological complexity
that may be underlying why these variants are associated with changes in *CYB561*expression.

54 1.3 Brain: ZNF439

The OTTERS association for *ZNF439* was driven by the lassosum approach, which 55 originally modeled 1,336 SNPs. This model yielded a highly significant association to 56 AD (ACAT-O_{CON} p = 2.21×10^{-52} ; p_{Lassosum} CON = 1.1×10^{-52} ; z_{Lassosum} = 9.94; R²_{Lassosum} = 57 5.7%). Through causal eQTL fine-mapping, we identified five credible sets each 58 containing a single causal eQTL and subsequent application of these SNPs to the 59 OTTERS approach led to the generation of a four SNP lassosum model demonstrating 60 slightly reduced model performance in terms of variance explained ($R^{2}_{Lassosum} = 5.0\%$) 61 but further strengthened the association to AD ($p_{Lassosum} = 3.79 \times 10^{-97}$; $z_{Lassosum} = 20.92$). 62 63 We further explored the functional annotations associated with the four SNPs within the 64 lassosum model. There were two SNPs (chr19 11890134 C T b38 & 65 chr19 11896203 G C b38) that were positively associated with ZNF439 expression 66 and these SNPs shared H3K36me3 marks indicative of active transcription. In addition, chr19 11890134 C T b38 was also enriched for several other markers of active 67 enhancers and promoters such as H3K27ac, H3K4me1, H3K4me3, and H3K9ac. In 68 69 comparison, the remaining two SNPs were negatively associated with the expression of *ZNF439* and all shared H3K9me3 markers which are indicative of transcriptionally
 repressive heterochromatin regions. Of note, one of the positively associated SNPs
 (chr19_11896203_G_C_b38) also had annotations for H3K9me3 indicating the
 epigenomic regulation of this SNP is complex.

74

75 *1.4* Blood: *MYBPC3*

Fine-mapping of *MYBPC3* yielded four credible sets each containing a single causal 76 eQTL. Restricting the OTTERS method to the credible causal eQTLs, the SDPR, 77 lassosum, and PRS-CS modeling approaches were able to explain only a negligible 78 proportion of gene expression, falling short of our $R^2>1$ % filtering threshold. In contrast, 79 the P+T methods used a two-SNP model and maintained a statistically significant 80 positive association with AD risk ($p_{P+T} 0.001 = 6.48 \times 10^{-44}$, $z_{P+T} 0.001 = 13.9$, $R^2_{P+T} 0.001 = 1\%$). 81 In terms of the functional relevance of these SNPs, chr11 47403380 G A b38 was 82 83 positively associated with the expression of MYBPC3 and this location corresponds with several epigenetic markers of active enhancers/promoters such as H3K27ac, 84 H3K4me1, H3K9ac. The second SNP chr11 47433036 G A b38 selected by the P+T 85 86 approaches was negatively associated with the expression of MYBPC3 and, while this location is associated with heterochromatin marks (i.e., H3K9me3), we also found some 87 markers of active transcription (H3K4me3, H3K36me3), which suggests location is not 88 89 sufficient alone to understand the full functional impact of this SNPs. Overall, this result illustrated how fine-mapping the causal eQTLs within a TWAS association could lead 90 91 sparse genetic models that were sufficiently powered to generate a similar strength 92 TWAS associations that were otherwise lost by the original method.

93 2 Elucidating the role of AD-TWAS associations

94 2.1 Brain: CYB561

CYB561 (Cytochrome B561) is a transmembrane monodehydroascorabate reductase 95 that serves a vital role in ascorbate-dehydroascorbate recycling within catecholamine 96 secretory vesicles in order to produce norepinephrine (NE) from dopamine [6]. In our 97 98 study, we found a negative association between the genetically regulated expression of CYB561 and AD risk (ACAT-O_{CON} $p = 1.99 \times 10^{-33}$) and validated that significantly lower 99 levels of CYB561 were found in AD brains relative to controls (t-test p=2.26×10⁻⁷). In 100 101 terms of the functional roles of CYB561, individuals with homozygous pathogenic mutations within CYB561 have been found to present with life-threatening orthostatic 102 hypotension, recurrent hypoglycemia, and low levels of norepinephrine [6]. Interestingly, 103 knockout CYB561 mice displayed significantly reduced whole brain levels of 104 norepinephrine [6]. In addition, another study found using the Drosophila mutant *nemy*, 105 106 which is the CYB561 homologue, that reduced levels of *nemy* lead to learning and memory deficits [7]. Previous studies have supported the role of NE in AD, as 107 researchers have found that the locus coeruleus (LC) which produces NE is one of the 108 109 first brain regions that degenerates during early stages of AD and that this loss corresponds with memory impairment [8]. Moreover, several in vitro studies have found 110 111 decreased amyloid-beta toxicity and increased cell viability in the presence of dopamine 112 and NE which further supports the therapeutic potential of NE modulation in AD [9]. Overall, our results provide an additional line of evidence to support the mechanistic 113 role of NE in AD risk and motivate further studies to assess the role of CYB561 114 115 expression in AD pathogenesis.

116 2.2 Brain: C3orf62

C3orf62 (Chromosome 3 Open Reading Frame 62) is a protein-coding gene associated 117 with spermatogenesis and male fertility. In our study, we found a positive association 118 between the genetically regulated expression of C3orf62 and AD risk (ACAT-OCON 119 $p=2.25\times10^{-59}$; $z_{LASSOSUM} = 10.63$; $R^{2}_{LASSOSUM} = 2.3\%$) and validated that significantly 120 higher expression levels of C3orf62 were found in AD brains relative to controls (Mean 121 Difference [Case vs. Controls]=0.024; t-test p=3.7×10⁻⁴). While little is known about the 122 role of C3orf62, one study exploring the spatiotemporal brain transcriptome through 123 various states of human development found C3orf62 to exhibit female-sex biased 124 differential gene expression in the dorsolateral prefrontal cortex and medial prefrontal 125 cortex during prenatal development [10]. In another study, two TWAS approaches 126 PrediXcan and MetaXcan identified significant associations between the genetically-127 regulated expression of C3orf62 and the chronic inflammatory condition Crohn's 128 Disease (CD) [11]. Finally, when we searched the GWAS catalog, several associations 129 between variants within or near C3orf62 are associated with depression. Overall, the 130 limited information available about C3orf62 requires further in vitro and in vivo 131 132 exploration for how its expression may be related to AD.

133 2.3 Brain: LYSMD4

134 LYSMD4 (LysM Domain Containing 4) is predicted to encode for an integral membrane

component. In our study, we found a negative association between the genetically

regulated expression of *LYSMD4* and AD risk (ACAT-O_{CON} $p = 5.58 \times 10^{-26}$; $z_{SDPR} = -8.63$;

137 R^{2} sDPR = 17.5%) and validated that significantly lower expression levels of *LYSMD4*

138 were found in AD brains relative to controls (Mean Difference [Case vs. Controls] = -

139 0.02; t-test $p=1.79\times10^{-5}$). There is little known about the role of LYSMD4 in the brain. One study by Lorenzi et al. 2018 explored the functional genetic mechanisms of brain 140 atrophy in AD and identified a SNP (rs1808723) within LYSMD4 that was negatively 141 associated within tibial nerve tissue to brain atrophy ($p=2.9\times10^{-24}$; Effect size = -0.66; 142 SE=0.057) [12]. Another study performed an epigenome-wide association of stroke 143 outcome and found a nominally significant association (p=9.75×10⁻⁶) between a CpG 144 methylation site within 200 bp of the transcription start site of LYSMD4 and stroke 145 outcome during the discovery phase of the analysis (N=643), but this finding did not 146 147 replicate (N=62) [13]. Overall, the role of LYSMD4 in the brain remains unclear. Therefore, further studies are needed to elucidate the function of LYSMD4 and its 148 association with AD. 149

150

151 SUPPLEMENTAL TEXT REFERENCES

- 152 [1] Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable
- selection in regression, with application to genetic fine mapping. J R Stat Soc Ser B

154 Stat Methodol 2020;82:1273–300. https://doi.org/10.1111/rssb.12388.

- [2] Gockley J, Montgomery KS, Poehlman WL, Wiley JC, Liu Y, Gerasimov E, et al.
- 156 Multi-tissue neocortical transcriptome-wide association study implicates 8 genes
- across 6 genomic loci in Alzheimer's disease. Genome Med 2021;13:76.
- 158 https://doi.org/10.1186/s13073-021-00890-2.
- [3] de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain
- 160 expression quantitative trait locus and network analyses reveal downstream effects
- and putative drivers for brain-related diseases. Nat Genet 2023;55:377–88.
- 162 https://doi.org/10.1038/s41588-023-01300-6.
- 163 [4] Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al.
- 164 New insights into the genetic etiology of Alzheimer's disease and related
- dementias. Nat Genet 2022;54:412–36. https://doi.org/10.1038/s41588-022-01024-
- 166 Z.
- 167 [5] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic
- 168 meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and
- implicates A β , tau, immunity and lipid processing. Nat Genet 2019;51:414–30.
- 170 https://doi.org/10.1038/s41588-019-0358-2.
- 171 [6] van den Berg MP, Almomani R, Biaggioni I, van Faassen M, van der Harst P, Silljé
- 172 HHW, et al. Mutations in CYB561 Causing a Novel Orthostatic Hypotension

173 Syndrome. Circ Res 2018;122:846–54.

174 https://doi.org/10.1161/CIRCRESAHA.117.311949.

- 175 [7] Iliadi KG, Avivi A, Iliadi NN, Knight D, Korol AB, Nevo E, et al. nemy encodes a
- 176 cytochrome b561 that is required for Drosophila learning and memory. Proc Natl
- Acad Sci U S A 2008;105:19986–91. https://doi.org/10.1073/pnas.0810698105.
- [8] Gutiérrez IL, Dello Russo C, Novellino F, Caso JR, García-Bueno B, Leza JC, et al.
- 179 Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target. Int J
- 180 Mol Sci 2022;23:6143. https://doi.org/10.3390/ijms23116143.
- 181 [9] Allnutt MA, Matera KM. Stabilization and Reduced Cytotoxicity of Amyloid Beta
- Aggregates in the Presence of Catechol Neurotransmitters. Neurochem Res

183 2024;49:379–87. https://doi.org/10.1007/s11064-023-04036-1.

[10] Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. Spatiotemporal

transcriptome of the human brain. Nature 2011;478:483–9.

- 186 https://doi.org/10.1038/nature10523.
- 187 [11] Fryett JJ, Inshaw J, Morris AP, Cordell HJ. Comparison of methods for
- transcriptome imputation through application to two common complex diseases.
- 189 Eur J Hum Genet EJHG 2018;26:1658–67. https://doi.org/10.1038/s41431-018-
- 190 **0176-5**.
- [12] Lorenzi M, Altmann A, Gutman B, Wray S, Arber C, Hibar DP, et al. Susceptibility of
- brain atrophy to TRIB3 in Alzheimer's disease, evidence from functional
- 193 prioritization in imaging genetics. Proc Natl Acad Sci U S A 2018;115:3162–7.
- 194 https://doi.org/10.1073/pnas.1706100115.

- 195 [13] Cullell N, Soriano-Tárraga C, Gallego-Fábrega C, Cárcel-Márquez J, Muiño E,
- 196 Llucià-Carol L, et al. Altered methylation pattern in EXOC4 is associated with
- 197 stroke outcome: an epigenome-wide association study. Clin Epigenetics
- 198 2022;14:124. https://doi.org/10.1186/s13148-022-01340-5.
- 199